fda warning compounded tirzepatide safety eli lilly retatrutide trials profile clinical The has issued letters to multiple companies marketing Starting Phase 3b Clinical Trial – Beware of Compounded Tirzepatide

Tirzepatide is suitable for adults facing obstacles in weight reduction through traditional methods like diet and exercise

Do not increase the dose early, even if you feel fine

IGF-1 LR3 Synonyms / Designations: IGF-1 LR3, Long Arg IGF-1, Insulin-Like Growth Factor-1 LR3, Recombinant IGF-1 analogue CAS Number: 946870-92-4 Molecular Formula: C400H625N111O115S9 Molecular Weight: 9117.5 g/mol Peptide Classification: Synthetic analogue of insulin-like growth factor-1 (IGF-1) Purity: 99 % (HPLC, typical) Appearance: White to off-white lyophilised powder Pack Size: 1 mg (total) Storage: Desiccated, protected from light, stored at 20 C Solubility: Soluble in sterile water and buffered aqueous solutions Description & Mechanism IGF-1 LR3 is a synthetic analogue of human insulin-like growth factor-1 (IGF-1) incorporating an arginine substitution at position 3 and an extended N-terminal sequence

Not a head-to-head study

Your provider will perform a thorough evaluation to verify whether tirzepatide is right for you